Induced Pluripotent Stem Cell (iPSC) Lines from a Family with Resistant Epileptic Encephalopathy Caused by Compound Heterozygous Mutations in SZT2 Gene.
Cecilia CattelaniIngrid BattistellaFrancesca Di LevaGiulia FioravantiFrancesco BenedicentiFranco StanzialChristine SchwienbacherFrancesca FanelliPeter P PramstallerAndrew A HicksLuciano ContiCorrado CortiPublished in: International journal of molecular sciences (2022)
Mutations in the SZT2 gene have been associated with developmental and epileptic encephalopathy-18, a rare severe autosomal recessive neurologic disorder, characterized by psychomotor impairment/intellectual disability, dysmorphic facial features and early onset of refractory seizures. Here we report the generation of the first induced pluripotent stem cell (iPSC) lines from a patient with treatment-resistant epilepsy, carrying compound heterozygous mutations in SZT2 (Mut1: c.498G>T and Mut2: c.6553C>T), and his healthy heterozygous parents. Peripheral blood mononuclear cells were reprogrammed by a non-integrating Sendai virus-based reprogramming system. The generated human iPSC lines exhibited expression of the main pluripotency markers, the potential to differentiate into all three germ layers and presented a normal karyotype. These lines represent a valuable resource to study neurodevelopmental alterations, and to obtain mature, pathology-relevant neuronal populations as an in vitro model to perform functional assays and test the patient's responsiveness to novel antiepileptic treatments.
Keyphrases
- early onset
- intellectual disability
- stem cells
- late onset
- induced pluripotent stem cells
- high glucose
- autism spectrum disorder
- endothelial cells
- diabetic rats
- case report
- poor prognosis
- genome wide
- drug induced
- oxidative stress
- dna methylation
- high throughput
- cell therapy
- binding protein
- long non coding rna
- transcription factor
- bone marrow
- subarachnoid hemorrhage
- embryonic stem cells